- Home
- PSNL vs SVRA Comparison
PSNL vs SVRA Comparison
Compare PSNL & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNL
- SVRA
- Stock Information
- Founded
- PSNL 2011
- SVRA N/A
- Country
- PSNL United States
- SVRA United States
- Employees
- PSNL N/A
- SVRA N/A
- Industry
- PSNL Medical Specialities
- SVRA Biotechnology: Pharmaceutical Preparations
- Sector
- PSNL Health Care
- SVRA Health Care
- Exchange
- PSNL Nasdaq
- SVRA Nasdaq
- Market Cap
- PSNL 460.7M
- SVRA 458.2M
- IPO Year
- PSNL 2019
- SVRA N/A
- Fundamental
- Price
- PSNL $4.72
- SVRA $2.69
- Analyst Decision
- PSNL Strong Buy
- SVRA Buy
- Analyst Count
- PSNL 4
- SVRA 7
- Target Price
- PSNL $7.81
- SVRA $9.86
- AVG Volume (30 Days)
- PSNL 1.1M
- SVRA 633.7K
- Earning Date
- PSNL 02-27-2025
- SVRA 03-06-2025
- Dividend Yield
- PSNL N/A
- SVRA N/A
- EPS Growth
- PSNL N/A
- SVRA N/A
- EPS
- PSNL N/A
- SVRA N/A
- Revenue
- PSNL $87,489,000.00
- SVRA N/A
- Revenue This Year
- PSNL $16.00
- SVRA N/A
- Revenue Next Year
- PSNL $1.29
- SVRA N/A
- P/E Ratio
- PSNL N/A
- SVRA N/A
- Revenue Growth
- PSNL 24.05
- SVRA N/A
- 52 Week Low
- PSNL $1.14
- SVRA $2.59
- 52 Week High
- PSNL $7.20
- SVRA $5.70
- Technical
- Relative Strength Index (RSI)
- PSNL 43.46
- SVRA 40.81
- Support Level
- PSNL $4.47
- SVRA $2.65
- Resistance Level
- PSNL $6.43
- SVRA $2.91
- Average True Range (ATR)
- PSNL 0.51
- SVRA 0.11
- MACD
- PSNL 0.00
- SVRA 0.01
- Stochastic Oscillator
- PSNL 12.50
- SVRA 23.08
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.